<2>Form DEF 14A Immunic Inc: A Comprehensive Analysis
<3>Introduction
Immunic Inc, a biopharmaceutical company focused on developing therapies for chronic inflammatory and autoimmune diseases, has filed its Form DEF 14A with the Securities and Exchange Commission (SEC). This document outlines the company’s annual meeting of shareholders, including the election of directors, the ratification of the appointment of the company’s independent registered public accounting firm, and the approval of the company’s 2023 equity compensation plan.
<3>The Company’s Background
Immunic Inc is a clinical-stage biopharmaceutical company based in New Jersey, USA. The company’s primary focus is on developing novel, small-molecule therapies for chronic inflammatory and autoimmune diseases. Its lead product candidate, vidofludimus calcium, is currently in Phase III clinical trials for the treatment of budsotensis.
<3>Form DEF 14A Content
The Form DEF 14A contains the following key information:
– < href='https://www.sec.gov/Archives/edgar/data/1425668/000142566819000013/immunic-defdidc14a.htm' target='_blank'>Notice of Annual Meeting of Shareholders
– < href='https